Oruka Therapeutics Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Very happy to have Oruka Therapeutics CEO Lawrence Klein with us this afternoon to talk about the story. Maybe I'll kick it over to Lawrence for a brief overview of the company, and then we'll get into a Q&A. Lawrence, over to you. Sure.
Thanks, Alex, and thanks to everyone for joining this afternoon. Oruka Therapeutics, we're focused on advancing the standard of care in psoriatic disease, and our pipeline is anchored around two co-lead programs, which we call ORKA-001 and ORKA-002, which are ultra-long-acting antibodies targeting what we believe are the two best targets in psoriatic disease, IL-23p19 and IL-17A/F. Both of these antibodies are now in phase II studies. We've read out phase II data from two independent phase II studies with ORKA-001 up to week 28 or month six, showing what really are, we think, best in indication efficacy figures, clearing the skin in moderate to severe patients at a rate of over 60% in both independent studies, which is very exciting. With the potential for dosing potentially once annually, with a six-month option, which is our intended TPP for that program.
There's never been a once annual dosed medication in any chronic immune disease, so we think that could capture the imagination in a new way and really be impactful for patients. We've got an important readout in December coming up that will help to elucidate just how well we maintain responses out to one year, and I'm sure we'll get into kind of the details around that readout. But what we like about our setup is that is intended to go into phase III in the first half of next year, and that's a big activity within the company right now, is preparing for that. But beyond that, we've got a nice kind of sequence of potential catalysts to grow our pipeline beyond ORKA-001. We're aiming to have psoriasis data for our ORKA-002 17A/F Bimzelx-like molecule in the first quarter of next year.
That molecule's also in an HS study, which is enrolling well. We haven't set a timeline on data yet, but that'll probably be the next data event. Beyond that, we have a third program, ORKA-004, which is an extended half-life TL1A, which we want to use in combination with both one and two. We think a combination of ORKA-002 plus ORKA-004 in HS, so a TL1A IL-17A/F combo in HS could be a very interesting way to potentially break through an efficacy ceiling in that disease, and maybe branch out even further with combinations beyond that. So lots of ambitious plans at Oruka and exciting things going on.
Great. Maybe I wanted to start thinking about psoriasis in particular. Psoriasis is the market where everyone points to a market that's been solved in the progression of dosing, et cetera, and how that's driven opportunity among some of these new next-gen agents. What kind of is the remaining unmet need in psoriasis that you're going after at this point?
Yeah, it's interesting. There's been a progression in the standard of care for psoriasis over the past maybe 30, 40 years from where we started with really broad immunosuppressive agents, steroids, and things of that nature, to targeted agents that address a very specific aspect of the immune system. It's interesting to talk to dermatologists who've been in the field through that whole trajectory. Some of them would say, when we first saw STELARA, which is an IL-23p40 antibody, they said, "Isn't this disease solved now? That's as good as it gets, right?" Then TREMFYA and SKYRIZI came along, and SKYRIZI is now on track to, I think, be the second-biggest drug in all of biopharma, second only to tirzepatide, because it clears the skin for a higher percentage of people and is dosed very infrequently and has a very, very clean safety profile.
Now people are trying to push that further by applying that same target, IL-23p19, in an oral format, so getting to an orally available agent that inhibits that same cytokine. What we've run into there is you end up with lower efficacy, and you still have to take a pill every day. What we've done at Oruka is we believe that actually maybe the ideal product profile, maybe really to solve this disease in a way that it really becomes hard to improve on, could be something as infrequently dosed as annual with very, very high rates of skin clearance. That's what we've started to show with ORKA-001, and we think we can further elucidate. We think this could be the end game in psoriasis.
We think it is a little hard to imagine what comes along beyond this, because I think these are clearly the two best targets in the disease. But yeah, we think there's still meaningful advancement.
Can you talk about the fundamental kind of biological insight around getting to that 60+% PASI 100 rates that you are seeing across two trials relative to the 40%-50% from SKYRIZI?
Yeah, a large component of that is exposure and response. It is really pretty simple, is how much antibody is in the bloodstream correlates with how strong the response is. The first IL-23 agents, it is very clear if you go back and look at how they were developed, they were not dose optimized. One very clear point of evidence is they are dosed much higher in IBD, and they were developed later in IBD. If you look at the way the psoriasis doses were originally selected, a lot of it had to do with how much could fit in an auto-injector at the time and the formulations that they had at the time, which were not quite what we are able to do today. They were not fully dose optimized.
They ended up using a higher dose in IBD to get higher efficacy, and then more data came out that suggested that if you went to higher exposures, you could potentially drive higher responses. That is what we picked up. We picked up that thread with ORKA-001, tested it at significantly higher doses than the approved IL-23s, and we saw those same very high response rates, close to 20 percentage points higher than other IL-23s at week 16, which is pretty remarkable.
Yeah, maybe let us talk about the designs of EVERLAST-A and EVERLAST-B, and basically the data that you have seen across both those studies at induction so far.
Yeah, those are randomized placebo-controlled studies, two independent studies in very different site footprints, so really very independent tests. One was a single dose level. EVERLAST-A was our 600 milligram dose, which was what we always thought would be our go-forward dose. EVERLAST-B is dose ranging, so it included three different dose levels. It was intended to satisfy a requirement that regulatory authorities like to see dose-ranging studies to justify a phase III dose. Both of those showed very similar efficacy at the 600 milligram dose of- low 60s PASI 100, mid 80s PASI 90.
I think it's interesting that that's very similar efficacy to the best in indication efficacy so far seen with Bimzelx.
Yeah. Which I think indicates that that may be a maximum efficacy of inhibiting the IL-23, IL-17 axis.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
